Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
In 2023, Eli Lilly synthesized injectable retatrutide, the first triple-action agonist targeting GLP-1, GIP, and glucagon receptors, which is currently undergoing Phase 3 clinical trials
Plays a role in the immune system by detecting antigens and triggering immune responses against invaders
Stimulates appetite and improves feed intake
Eli Lilly's TRIUMPH trials describe once-weekly subcutaneous injection
Avoid self-treatment: Never try to manage vitamin levels on your own without guidance, as doing so may mask or worsen serious health issues
How do metformin and GLP-1 agonists compare for weight management in women with PCOS
US$ 20.53
US$ 24.16
US$ 27.85
US$ 27.36
